Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8928
  • E-ISSN: 2212-3970

Abstract

Background

The tumor burden before chimeric antigen receptor T (CAR-T) cell therapy was one of the critical factors affecting the prognosis of lymphoma. It was a challenge to effectively reduce the tumor burden of relapsed/refractory large B-cell lymphoma with p53 mutation.

Objective

Here, we have presented a case of relapsed/refractory large B-cell lymphoma with p53 mutation being controlled by the treatment with daratumumab and venetoclax, followed by CAR-T cell therapy.

Case Presentation

The patient was a 56-year-old female who was diagnosed with relapsed/refractory diffuse large B cell lymphoma (DLBCL) transformed from follicular lymphoma. The patient was treated with daratumumab, venetoclax, and GEMOX (gemcitabine and oxaliplatin) under the guidance of high-throughput drug sensitivity analysis. We used a CD38 positive lymphoma cell line with p53 mutation to construct tumor models for validating the anti-lymphoma effect of the combination therapy of daratumumab and venetoclax.

Results

The patient achieved a complete metabolic response after treatment with daratumumab, venetoclax, and GEMOX. Then, she further achieved a complete molecular response after she subsequently received CAR-T cell therapy, and she has been living without a lymphoma recurrence. The results from the animal study showed that the combination of daratumumab and venetoclax could significantly enhance the antitumor effect on CD38-positive lymphoma with p53 mutation.

Conclusion

The results from our successful case and animal experiments provide new avenues for the treatment of relapsed/refractory large B-cell lymphoma with p53 mutation. Further clinical trials are reuqired to treat CD38-positive lymphoma with the combination of daratumumab and venetoclax.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928273058231128073414
2024-01-23
2025-09-20

  • From This Site

    /content/journals/pra/10.2174/0115748928273058231128073414
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CoiffierB. LepageE. BrièreJ. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N. Engl. J. Med.2002346423524210.1056/NEJMoa011795 11807147
     [Google Scholar]
  2. MontotoS. DaviesA.J. MatthewsJ. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.J. Clin. Oncol.200725172426243310.1200/JCO.2006.09.3260 17485708
     [Google Scholar]
  3. LinkB.K. MaurerM.J. NowakowskiG.S. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.J. Clin. Oncol.201331263272327810.1200/JCO.2012.48.3990 23897955
     [Google Scholar]
  4. HiragaJ. TomitaA. SugimotoT. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.Blood2009113204885489310.1182/blood‑2008‑08‑175208 19246561
     [Google Scholar]
  5. van ImhoffG.W. McMillanA. MatasarM.J. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-Cell Lymphoma: The orcharrd study.J. Clin. Oncol.201735554455110.1200/JCO.2016.69.0198 28029326
     [Google Scholar]
  6. BradyC.A. AttardiL.D. p53 at a glance.J. Cell Sci.2010123152527253210.1242/jcs.064501 20940128
     [Google Scholar]
  7. PasqualucciL. KhiabanianH. FangazioM. Genetics of follicular lymphoma transformation.Cell Rep.20146113014010.1016/j.celrep.2013.12.027 24388756
     [Google Scholar]
  8. Xu-MonetteZ.Y. WuL. ViscoC. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.Blood2012120193986399610.1182/blood‑2012‑05‑433334 22955915
     [Google Scholar]
  9. DoderoA. GuidettiA. MarinoF. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: Impact of TP53 mutations on clinical outcome.Haematologica202110751153116210.3324/haematol.2021.278638 34289655
     [Google Scholar]
  10. ChongE.A. RuellaM. SchusterS.J. Five-year outcomes for refractory b-cell lymphomas with CAR T-Cell Therapy.N. Engl. J. Med.2021384767367410.1056/NEJMc2030164 33596362
     [Google Scholar]
  11. ShouvalR. Alarcon TomasA. FeinJ.A. Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.J. Clin. Oncol.202240436938110.1200/JCO.21.02143 34860572
     [Google Scholar]
  12. VercellinoL. Di BlasiR. KanounS. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.Blood Adv.20204225607561510.1182/bloodadvances.2020003001 33180899
     [Google Scholar]
  13. HayK.A. HanafiL.A. LiD. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy.Blood2017130212295230610.1182/blood‑2017‑06‑793141 28924019
     [Google Scholar]
  14. JacobsonCA LockeFL MaL Real-World evidence of axicabtagene ciloleucel for the treatment of large b cell lymphoma in the united states.Transplant Cell Ther20226367220319
     [Google Scholar]
  15. WangM. MunozJ. GoyA. KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma.N. Engl. J. Med.2020382141331134210.1056/NEJMoa1914347 32242358
     [Google Scholar]
  16. AwasthiR. PacaudL. WaldronE. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.Blood Adv.20204356057210.1182/bloodadvances.2019000525 32045475
     [Google Scholar]
  17. LuD.Y. LuT.R. Drug sensitivity testing for cancer therapy, technique analysis and trend.Rev Clin Exp Pharmacol202118131110.2174/2772432816666210910104649
     [Google Scholar]
  18. VockovaP. SvatonM. KarolovaJ. PokornaE. VokurkaM. KlenerP. Anti-CD38 therapy with daratumumab for relapsed/refractory cd20-negative diffuse large b-cell lymphoma.Folia Biol2020661172310.14712/fb2020066010017 32512655
     [Google Scholar]
  19. Vidal-CrespoA. Matas-CéspedesA. RodriguezV. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.Haematologica202010541032104110.3324/haematol.2018.211904 31296574
     [Google Scholar]
  20. SallesG. GopalA.K. MinnemaM.C. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.Clin. Lymphoma Myeloma Leuk.201919527528410.1016/j.clml.2018.12.013 30795996
     [Google Scholar]
  21. DavidsM.S. RobertsA.W. SeymourJ.F. Phase I First-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma.J. Clin. Oncol.201735882683310.1200/JCO.2016.70.4320 28095146
     [Google Scholar]
  22. BahlisN.J. BazR. HarrisonS.J. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).J. Clin. Oncol.202139323602361210.1200/JCO.21.00443 34388020
     [Google Scholar]
  23. NakamuraA. SuzukiS. KanasugiJ. Synergistic effects of venetoclax and daratumumab on antibody-dependent cell-mediated natural killer cytotoxicity in multiple myeloma.Int. J. Mol. Sci.202122191076110.3390/ijms221910761 34639102
     [Google Scholar]
  24. VogiatziF. HeymannJ. MüllerK. Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.Blood Adv.20226164847485810.1182/bloodadvances.2022007364 35820018
     [Google Scholar]
  25. RoddieC. NeillL. OsborneW. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.Blood Adv.20237122872288310.1182/bloodadvances.2022009019 36724512
     [Google Scholar]
/content/journals/pra/10.2174/0115748928273058231128073414
Loading
Treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy: Case Report and Animal Study
Recent Patents on Anti-Cancer Drug Discovery 20, 513 (2025); https://doi.org/10.2174/0115748928273058231128073414
/content/journals/pra/10.2174/0115748928273058231128073414
/content/journals/pra/10.2174/0115748928273058231128073414
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): chimeric antigen receptor; daratumumab; Large B-cell lymphoma; p53 mutation; T cell therapy; venetoclax

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test